New insights into the pathophysiology and management of bone disease in multiple myeloma

This publication has 100 references indexed in Scilit:

• Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre‐treatment levels of S‐ICTP and U‐Ntx are predictive for early progression of the bone disease during standard chemotherapy
  British Journal of Haematology, 2003
• A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
  Cancer, 2003
• Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma
  Blood, 2002
• American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
  Journal of Clinical Oncology, 2002
• Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
  Cancer, 2001
• Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial
  British Journal of Haematology, 1998
• Bisphosphonates
  European Journal Of Cancer, 1998
• Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
  Journal of Clinical Oncology, 1998
• Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy‐terminal telopeptide of type I collagen (ICTP)
  British Journal of Haematology, 1997
• Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
  New England Journal of Medicine, 1996